digital currency comparison Top People also ask

South Korea's exports increased by 12.4% and imports increased by 11.6% from December 1 to 10. South Korea's chip exports increased by 43% year-on-year from December 1 to 10.Institution: In November, the average price of second-hand residential buildings in Baicheng dropped by 0.57% month-on-month. According to the 100-city price index of China's real estate index system, in November 2024, the average price of second-hand residential buildings in Baicheng fell by 0.57% month-on-month, narrowing by 0.03 percentage points from last month. It fell by 7.29% year-on-year. In November, the average price of second-hand residential buildings in the top ten cities fell by 0.17% month-on-month, which was 0.16 percentage points lower than that of the previous month. It fell by 7.16% year-on-year, and the decline was narrowed by 0.36 percentage points from the previous month. In terms of cities, the prices of second-hand houses in Shenzhen and Chengdu rose by 0.21% and 0.12% respectively. Nanjing had the largest decline from the previous month, with 0.60%; Wuhan, Hangzhou and Tianjin followed closely, with decreases of 0.43%, 0.42% and 0.31% respectively. Guangzhou, Shanghai and Beijing all experienced month-on-month declines of 0.1%-0.3%; Chongqing (the main city) has the smallest decline of 0.07%. In terms of year-on-year, Wuhan and Nanjing experienced large year-on-year declines, accounting for 10.82% and 10.24% respectively. Chongqing (the main city), Beijing, Hangzhou and Shanghai all experienced year-on-year declines of 7%-9%; The prices of second-hand houses in Tianjin, Guangzhou and Chengdu all fell by 5-7% year-on-year; Shenzhen fell by 4.42% year on year.South Korean Finance Minister and US Treasury Secretary Yellen confirmed that they will work closely together.

Argentine President Millai: Argentines can now trade in any currency.Monetary policy has turned to "moderate easing", and experts say that it is expected to make greater efforts to lower the RRR and cut interest rates. The the Political Bureau of the Communist Party of China (CPC) Central Committee meeting held on December 9 changed the orientation of monetary policy from "steady" to "moderate easing" next year. Experts said that under the orientation of "moderate easing", the monetary policy space was further opened. In terms of total amount, it is more reasonable and sufficient to maintain liquidity; In terms of price, appropriately reducing the financing cost will better reflect the effectiveness of monetary policy. Next year, even greater RRR cuts and interest rate cuts can be expected. In addition to lowering the RRR and cutting interest rates, experts said that structural monetary policy tools, buying government bonds, open market buyout reverse repurchase and other operations are expected to continue to expand the scale, increase the frequency of use, and continuously enhance the effectiveness and pertinence of monetary policy. (CSI)Japan's producer price in November increased by 0.3% month-on-month, and it is estimated to increase by 0.2%. Japan's producer price in November increased by 3.7% year-on-year, and it is estimated to increase by 3.4%.

On the morning of December 9, Leo, Party Secretary and Chairman of Shanghai Electric Group, went to Seoul, South Korea, and held talks with Zhao Xianjun, President of Xiaoxing Group. The two sides had in-depth exchanges on joint ventures and cooperation in the field of new energy. During the talks, the two sides also discussed the cooperation potential in the fields of hydrogen energy and power grid equipment, sought cooperation opportunities in technology research and development, project investment and market development, and jointly explored cooperative development models in the field of new energy to meet the challenges brought by global energy transformation.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.Guotai Junan's annual strategy for innovative drugs in 2025: innovative pharmaceutical companies have accelerated into the harvest period, and the valuation has been at a historical low in the past five years. Guotai Junan said that the centralized purchasing policy has become stable, mature and normalized, and the marginal impact has weakened. Innovative drugs have gained policy inclination in the medical insurance negotiation. In the past two years, the policy has continued to promote pharmaceutical innovation, and the top-level design and local supporting chain support the development of innovative drugs. Commercial insurance is expected to bring new growth momentum to China's pharmaceutical market, and the overall industry trend is upward. At present, the trend of innovative drug industry is improving, the supply continues to accelerate, and a number of domestic innovative drugs are approved soon, which is expected to drive a new round of heavy volume. At the same time, the commercialization has achieved remarkable results and has occupied a dominant position in some sub-sectors. Pharma's performance continued to differentiate, and innovative drugs and just-needed drugs performed well. Biotech commercialization continues to increase, per capita yield continues to increase, the node of turning losses is approaching, and innovation ushers in the harvest period. Horizontal comparison: compared with overseas peers, the overall valuation of domestic innovative pharmaceutical companies is in a historically low range; Vertical comparison: the valuation of SW- pharmaceutical biology and SW- chemical preparations is at a historical low in the past five years, and it is expected that the valuation of subsequent sectors will pick up.